Loading
Latest filing published 04 Jun 2024 for Terns Pharmaceuticals, Inc., €20k.
Not enough history yet: 1 closed purchase, at least 2 are needed.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
All filings by Seokho Bryan Yoon on record concern Terns Pharmaceuticals, Inc., in the capacity of chief executive. The record holds 6 filings, for trades running from 31 May 2022 to 31 May 2024.
Every open-market trade on record is a purchase: 5 purchases worth €46k, and no sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 1 share grant. 2024 to date brings 1 purchase and no sales.
A typical purchase (the median) is worth €10k. Clusters matter here: 5 out of 5 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster.
The record was last updated on 4 June 2024 with an open-market purchase (€20k) in Terns Pharmaceuticals, Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
6 of 5 declarations